Gilead Sciences Inc. closed 7.92% below its 52-week high of $119.96, which the company achieved on March 10th.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” first quarter 2025 ...

It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

We’re proud to share that “The Adventure Jar,” a children’s book supporting families impacted by metastatic breast cancer (MBC), has received two 2025 Bronze Anvil Awards from the Public Relations ...

The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...

The cuts will shutter two major HIV vaccine research efforts, and a National Institutes of Health senior official said the ...

Median PFS increased from 1.94 months with single-agent fulvestrant to 5.32 months with the addition of ipatasertib. Patients ...

Herpes simplex virus type 1 (HSV-1) is associated with an increased risk for Alzheimer disease (AD) based on real-world data from the United States.

TWN calls for urgent need of stronger scrutiny in granting patents to avoid evergreening: Our Bureau, New Delhi Tuesday, June 3, 2025, 08:00 Hrs [IST] Third World Network (TWN), a ...

Shares of Gilead Sciences Inc. GILD slid 1.06% to $108.91 Monday, on what proved to be an all-around favorable trading ...